Cargando…
Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer
In this article, we focus on a variety of immunosuppression scenarios and whether multikinase inhibitors, as systemic therapy for advanced thyroid carcinoma (TC), could be useful for the treatment of immunocompromised patients with TC. Lenvatinib and sorafenib, among other MKIs, have become the stan...
Autor principal: | Basté Rotllan, Neus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9537054/ https://www.ncbi.nlm.nih.gov/pubmed/36202608 http://dx.doi.org/10.1002/cam4.5106 |
Ejemplares similares
-
Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019) -
Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim, Sina, et al.
Publicado: (2014) -
Emerging role of multikinase inhibitors for refractory thyroid cancer
por: Perez, Cesar A, et al.
Publicado: (2012) -
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
por: Stjepanovic, Neda, et al.
Publicado: (2014) -
Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
por: Zafón, Carles, et al.
Publicado: (2022)